Non Invasive Diagnostic of Endometrial Receptivity
Launched by IGENOMIX · Apr 27, 2012
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Oocyte donors undergoing controlled ovarian stimulation
- • Regular menstrual cycles
- • no abnormal karyotype
- • generally healthy
- • BMI 19-29 Kg/m2 (both inclusive)
- • 18 to 35 years old.
- Exclusion criteria:
- • -patients diagnosed with endometriosis and/or endometritis.
About Igenomix
Igenomix is a leading global biotechnology company specializing in reproductive genetics and advanced genomic solutions. Committed to enhancing reproductive health, Igenomix provides innovative testing services that empower individuals and healthcare providers with critical information for informed decision-making in fertility treatments. With a strong emphasis on research and development, Igenomix leverages cutting-edge technologies to deliver accurate genetic assessments, facilitating personalized approaches to reproductive care. The company's dedication to excellence and patient-centric solutions positions it as a trusted partner in the field of reproductive medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Valencia, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials